Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer
Sponsor: NewLink Genetics Corporation
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from NewLink Genetics Corporation
- Non-small Cell Lung Cancer · Phase PHASE1 · Jan 2021
- Metastatic Melanoma · Phase PHASE2 · Jan 2021
- Pancreatic Cancer · Dec 2020
- Melanoma · Phase PHASE2 · Nov 2019
- Ovarian Cancer · Phase PHASE1/PHASE2 · Oct 2018
More terminations from NewLink Genetics Corporation
Listed as NCT02405585, this PHASE2 trial focuses on Pancreatic Cancer and Pancreatic Carcinoma Non-resectable and remains terminated or withdrawn. Sponsored by NewLink Genetics Corporation, it has been updated 9 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Mar 2019 — Jun 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NewLink Genetics Corporation
For direct contact, visit the study record on ClinicalTrials.gov .